Nine new members appointed to America’s Advisory Committee on Immunization Practices (ACIP) have financial ties to Big Pharma, or have publicly promoted vaccines.

New appointees to US vaccine advisory committee have ties to Big Pharma 

ACIP is said to be an autonomous group of experts not affiliated with the federal government.

Children’s Health Defense reported on Wednesday massive conflict of interest concerns for the new appointees who will be advising the Centers for Disease Control and Prevention (CDC) on vaccine recommendations. 

The report points out that most of the appointees have received grant funding or consulting fees from major pharmaceutical companies like Pfizer, Moderna, and Merck:

  • Dr. Denise Jamieson: Known for promoting COVID vaccines for pregnant women and receiving funding from the CDC for COVID-19 vaccination promotion.
  • Dr. Yvonne Maldonado: Received research funding from Pfizer and advocated for testing COVID vaccines in children.
  • Dr. Robert Schechter: Serves as a public advocate on various HHS committees and has a background with the California Department of Public Health.
  • Dr. Albert Shaw: Advocated for COVID-19 vaccination and has ties to pharmaceutical companies.
  • Dr. Edwin Asturias: A global vaccine researcher with consulting fees from major pharmaceutical companies like Merck.
  • Dr. Noel Brewer: Known for developing the “Announcement Approach” to HPV vaccination and consulting for Merck.
  • Dr. Helen Chu: Has ties to pharmaceutical companies, Gates ventures, and advocates for the RSV vaccine.

The cozy relationship between Big Pharma and vaccine safety advisors isn’t anything new, of course. In December 2022, a member from Pfizer’s Independent Data Safety Monitoring Board admitted in court that she was also on the pharmaceutical company’s payroll. 

FDA removes informed consent for “minimal risk” 

Last month, the Food and Drug Administration’s (FDA) removed the requirement to get informed consent from human participants for what they call “minimal risk” studies.

The FDA claimed the policy change will provide cost savings and healthcare advances. 

Share this story

Donate now to keep us on the front lines:

Help Keep your News Free

It's crucial we stay in touch

Big Tech wants to censor us, that’s why you need to stay in touch.

YOU MIGHT ALSO LIKE THESE...

Trending News

“It is a scandal:” UK bans puberty blockers for youth under 18, citing a lack of evidence that they’re safe.

Mike Campbell

December 11, 2024

Trending News

Rachel Gilmore tells parliamentary committee that pushback against things like DEI and giving puberty blockers to kids is not only hateful, but it’s helping Russia.

Mike Campbell

December 11, 2024

Trending News

The Department of National Defence says they didn’t fund the survey asking if CAF members have ever purchased “extremism merchandise” such as a Make Canada Great Again hat. But records show the feds gave the same two researchers $50k in 2020 to “support a survey and analysis of the policies that govern hateful conduct and right-wing extremism in the CAF.”

Mike Campbell

December 9, 2024

Trending News

Trudeau tells grieving Indigenous mothers asking for changes to policing that Canada has “built-in colonialism.”

TCS Wire

December 6, 2024

Trending News

Liberals are going after legal firearm owners, again, within one year of the next election.

TCS Wire

December 5, 2024

Trending News

It’s unclear whether this is more embarrassing for the Government of Canada or for academia.

Mike Campbell

December 4, 2024

Want to join the conversation?

Sign up now to be able to like, comment and reply to other members. A full membership to our site includes:

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.